TECX
NASDAQTectonic Therapeutic Inc.
Price$20.67-0.42 (-1.99%)
01:30 PM07:45 PM
News · 26 weeks410%
2026-04-192026-10-11
Mix2190d
- Insider12(57%)
- SEC Filings5(24%)
- Other3(14%)
- Analyst1(5%)
Latest news
25 items- ANALYSTUBS initiated coverage on Tectonic Therapeutic with a new price targetUBS initiated coverage of Tectonic Therapeutic with a rating of Neutral and set a new price target of $26.00
- INSIDERChief Financial Officer Lochner Daniel covered exercise/tax liability with 520 shares, decreasing direct ownership by 0.89% to 58,024 units (SEC Form 4) to cover taxes4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Scientific Officer Mcnamara Peter covered exercise/tax liability with 444 shares and sold $12,349 worth of shares (536 units at $23.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 54,305 units (SEC Form 4) to cover withholding tax4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 525 shares, decreasing direct ownership by 0.78% to 67,157 units (SEC Form 4) to satisfy withholding tax4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Executive Officer Reicin Alise covered exercise/tax liability with 1,545 shares, decreasing direct ownership by 0.50% to 309,078 units (SEC Form 4) (for withholding tax)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Business Officer Schwabish Marc covered exercise/tax liability with 411 shares, decreasing direct ownership by 0.91% to 44,903 units (SEC Form 4) (withholding obligation)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECSEC Form 8-K filed by Tectonic Therapeutic Inc.8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteersCompany plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a Phase 2 clinical trial in parallel in patients with moderate-to-severe HHT in early 2027 WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"
- INSIDERSEC Form 4 filed by Chief Executive Officer Reicin Alise4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Ruddy Marcella K.4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Lochner Daniel4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Schwabish Marc4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Mcnamara Peter4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- PRTectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceWATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Morgan Stanley 24th Annual Global Healthcare Conference Date:September 14, 2026Time:5:35 PM ETLocation:New York, NYFormat:Fireside ChatPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link
- SECSEC Form 144 filed by Tectonic Therapeutic Inc.144 - Tectonic Therapeutic, Inc. (0001681087) (Subject)
- INSIDERChief Scientific Officer Mcnamara Peter exercised 43 shares at a strike of $14.71 and sold $1,570 worth of shares (43 units at $36.52) as part of a pre-agreed trading plan (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECSEC Form 144 filed by Tectonic Therapeutic Inc.144 - Tectonic Therapeutic, Inc. (0001681087) (Subject)
- INSIDERChief Scientific Officer Mcnamara Peter sold $1,505 worth of shares (43 units at $35.00) as part of a pre-agreed trading plan and exercised 43 shares at a strike of $14.71 (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECSEC Form 10-Q filed by Tectonic Therapeutic Inc.10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business HighlightsEnrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction ("PH-HFpEF") with topline results anticipated in early Q1 2027TX45 APEX Phase 2 clinical trial Independent Data Monitoring Committee ("IDMC") met in July 2026 and recommended continuation of the study without modificationTX2100, a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT"), completed dosing of the six single dose healthy volunteer cohorts in the Phase 1a clinical trial, with topline results anticipated by end of Q3 2026Cash and cash equivalents were $227.1 million as of June 30, 2026, including approximately
- INSIDERChief Scientific Officer Mcnamara Peter exercised 172 shares at a strike of $14.71 and sold $6,020 worth of shares (172 units at $35.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Executive Officer Reicin Alise covered exercise/tax liability with 924 shares, decreasing direct ownership by 0.30% to 310,623 units (SEC Form 4) to cover taxes4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Lochner Daniel4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
TECX FAQ
6 questionsWhere does TECX stock trade?
Tectonic Therapeutic Inc. (TECX) is listed on NASDAQ.What sector and industry is TECX in?
Tectonic Therapeutic Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tectonic Therapeutic Inc. go public?
Tectonic Therapeutic Inc. (TECX) completed its IPO in 2018.What are analysts saying about TECX?
Tectonic Therapeutic Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $2600.00 price target on 2026-10-12. Recent price targets cluster around $2600.00.What companies are similar to TECX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare TECX side-by-side with any of them on Quantisnow.How can I track TECX on Quantisnow?
Quantisnow aggregates Tectonic Therapeutic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TECX to receive live email and push alerts on every new disclosure.